Healio

‘More options’ flood IBD market as rival IL-23 drugs face off with Stelara biosimilar boom

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Three new IL-23 inhibitors have been approved for IBD, ...
Medscape

IL-23 Inhibitors Appear Safe in Psoriasis With Cancer

A study found low rates of cancer recurrence, progression, or new malignancy among patients with psoriasis and prior neoplasia receiving interleukin-23 (IL-23) inhibitors. Researchers conducted a ...
Seeking Alpha

TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ...

"For many patients, having a subcutaneous induction option is an important step forward—offering the flexibility of at-home administration after proper training without compromising efficacy," said ...
Seeking Alpha

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

1 One case of infusion reaction and one case of pruritus, both Grade 1 and resolved without medication. 2 One case of asymptomatic increased lipase, isolated to Day 43 post-dose (Grade 3); One case of ...
Morningstar

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety ...